Previous Article | Next Article ![]()
Infection and Immunity, August 2005, p. 5065-5073, Vol. 73, No. 8
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.8.5065-5073.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104,1 Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 021152
Received 12 January 2005/ Returned for modification 20 February 2005/ Accepted 10 March 2005
Listeria monocytogenes is a gram-positive intracellular pathogen that can enter phagocytic and nonphagocytic cells and colonize their cytosols. Taking advantage of this property to generate an intracellular vaccine delivery vector, we previously described a mutant strain of L. monocytogenes,
dal
dat, which is unable to synthesize cell wall by virtue of deletions in two genes (dal and dat) required for D-alanine synthesis. This highly attenuated strain induced long-lived protective systemic and mucosal immune responses in mice when administered in the transient presence of D-alanine. We have now increased the usefulness of this organism as a vaccine vector by use of an inducible complementation system that obviates the need for exogenous D-alanine administration. The strain expresses a copy of the Bacillus subtilis racemase gene under the control of a tightly regulated isopropyl-ß-D-thiogalactopyranoside (IPTG)-inducible promoter present on a multicopy plasmid. This bacterium demonstrates strict dose-dependent growth in the presence of IPTG. After removal of inducer, bacterial growth ceased within two replication cycles. Following infection of mice in the absence of IPTG or D-alanine, the bacterium survived in vivo for less than 3 days. Nevertheless, a single immunization elicited a state of long-lasting protective immunity against wild-type L. monocytogenes and induced a subset of effector listeriolysin O-specific CD11a+ CD8+ T cells in spleen and other tissues that was strongly enhanced after secondary immunization. This improved L. monocytogenes vector system may have potential use as a live vaccine against human immunodeficiency virus, other infectious diseases, and cancer.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|